Literature DB >> 11701661

Clinical review 138: Anabolic-androgenic steroid therapy in the treatment of chronic diseases.

S Basaria1, J T Wahlstrom, A S Dobs.   

Abstract

The purpose of this study was to review the preclinical and clinical literature relevant to the efficacy and safety of anabolic androgen steroid therapy for palliative treatment of severe weight loss associated with chronic diseases. Data sources were published literature identified from the Medline database from January 1966 to December 2000, bibliographic references, and textbooks. Reports from preclinical and clinical trials were selected. Study designs and results were extracted from trial reports. Statistical evaluation or meta-analysis of combined results was not attempted. Androgenic anabolic steroids (AAS) are widely prescribed for the treatment of male hypogonadism; however, they may play a significant role in the treatment of other conditions as well, such as cachexia associated with human immunodeficiency virus, cancer, burns, renal and hepatic failure, and anemia associated with leukemia or kidney failure. A review of the anabolic effects of androgens and their efficacy in the treatment of these conditions is provided. In addition, the numerous and sometimes serious side effects that have been known to occur with androgen use are reviewed. Although the threat of various side effects is present, AAS therapy appears to have a favorable anabolic effect on patients with chronic diseases and muscle catabolism. We recommend that AAS can be used for the treatment of patients with acquired immunodeficiency syndrome wasting and in severely catabolic patients with severe burns. Preliminary data in renal failure-associated wasting are also positive. Advantages and disadvantages should be weighed carefully when comparing AAS therapy to other weight-gaining measures. Although a conservative approach to the use of AAS in patients with chronic diseases is still recommended, the utility of AAS therapy in the attenuation of severe weight loss associated with disease states such as cancer, postoperative recovery, and wasting due to pulmonary and hepatic disease should be more thoroughly investigated.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11701661     DOI: 10.1210/jcem.86.11.7983

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  68 in total

1.  Chronic anabolic androgenic steroid exposure alters corticotropin releasing factor expression and anxiety-like behaviors in the female mouse.

Authors:  Beth A Costine; Joseph G Oberlander; Matthew C Davis; Carlos A A Penatti; Donna M Porter; Robert N Leaton; Leslie P Henderson
Journal:  Psychoneuroendocrinology       Date:  2010-05-26       Impact factor: 4.905

Review 2.  Mad men, women and steroid cocktails: a review of the impact of sex and other factors on anabolic androgenic steroids effects on affective behaviors.

Authors:  Marie M Onakomaiya; Leslie P Henderson
Journal:  Psychopharmacology (Berl)       Date:  2016-01-12       Impact factor: 4.530

3.  Graded inhibition of pulsatile luteinizing hormone secretion by a selective gonadotropin-releasing hormone (GnRH)-receptor antagonist in healthy men: evidence that age attenuates hypothalamic GnRH outflow.

Authors:  Paul Y Takahashi; Peter Y Liu; Pamela D Roebuck; Ali Iranmanesh; Johannes D Veldhuis
Journal:  J Clin Endocrinol Metab       Date:  2005-03-01       Impact factor: 5.958

Review 4.  Testosterone and doping control.

Authors:  C Saudan; N Baume; N Robinson; L Avois; P Mangin; M Saugy
Journal:  Br J Sports Med       Date:  2006-07       Impact factor: 13.800

Review 5.  Biological augmentation of rotator cuff tendon repair.

Authors:  David Kovacevic; Scott A Rodeo
Journal:  Clin Orthop Relat Res       Date:  2008-02-10       Impact factor: 4.176

Review 6.  Neuropsychiatric effects of prescription drug abuse.

Authors:  Jason P Caplan; Lucy A Epstein; Davin K Quinn; Jonathan R Stevens; Theodore A Stern
Journal:  Neuropsychol Rev       Date:  2007-08-16       Impact factor: 7.444

7.  Saikosaponin a Inhibits Cigarette Smoke-Induced Oxidant Stress and Inflammatory Responses by Activation of Nrf2.

Authors:  Ru-Jie Chen; Xian-Yang Guo; Bi-Huan Cheng; Yu-Qiang Gong; Bin-Yu Ying; Meng-Xiang Lin
Journal:  Inflammation       Date:  2018-08       Impact factor: 4.092

Review 8.  Anabolic steroid abuse and dependence.

Authors:  Kirk J Brower
Journal:  Curr Psychiatry Rep       Date:  2002-10       Impact factor: 5.285

9.  Dihydrotestosterone activates the MAPK pathway and modulates maximum isometric force through the EGF receptor in isolated intact mouse skeletal muscle fibres.

Authors:  M M Hamdi; G Mutungi
Journal:  J Physiol       Date:  2009-12-14       Impact factor: 5.182

10.  Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial.

Authors:  Adrian S Dobs; Ralph V Boccia; Christopher C Croot; Nashat Y Gabrail; James T Dalton; Michael L Hancock; Mary A Johnston; Mitchell S Steiner
Journal:  Lancet Oncol       Date:  2013-03-14       Impact factor: 41.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.